EPISODE · Mar 6, 2023 · 15 MIN
AptaTargets y sus avances contra el ictus isquémico
from Biotecnología Capital · host Capital Radio
Recibimos a David Segarra, CEO y co-fundador de aptaTargets, que nos habla de los avances con el fármaco ApTOLL para mejorar el pronóstico en ese tipo de ictus.
Embed this episode
NOW PLAYING
AptaTargets y sus avances contra el ictus isquémico
0:00
15:56
1×
No transcript for this episode yet
Similar Episodes
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Biotecnología Capital?
This episode is 15 minutes long.
When was this Biotecnología Capital episode published?
This episode was published on March 6, 2023.
Can I download this Biotecnología Capital episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!